Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 14 Nov 2017
At a glance
- Drugs PDR 001 (Primary)
- Indications Breast cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis
- 07 Nov 2017 Planned End Date changed from 12 Jul 2018 to 20 May 2019.
- 15 May 2017 Planned End Date changed from 12 Aug 2018 to 12 Jul 2018.
- 15 May 2017 Planned primary completion date changed from 12 Aug 2018 to 13 Feb 2018.